Oncology News

LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, will present the latest cancer research at the AACR Annual Meeting 2025, which will take place April 25 to 30 in Chicago. City of Hope experts will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet to present partner data showing how needle-free can be expected to enhance vaccine immune response in difficult-to-treat cancer patients....

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs....

DUBLIN--(BUSINESS WIRE)--The "Solid Tumors 2025: Technologies, Diagnostics & Therapeutics" conference has been added to ResearchAndMarkets.com's offering. This conference explores innovations in technology development, the development of early-screening methodologies, liquid biopsies, various diagnostic and current therapeutic modalities addressing several classes of solid tumors. Given that solid tumors represent a challenging target in oncology, the goal of this conference is to bring tog...

SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences (“BigHat”), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a strategic collaboration with Eli Lilly and Company (“Lilly”). In this collaboration, BigHat will deploy its Milliner platform, a suite of state-of-the-art ML technologies integrated with a synthetic biology-based high-speed wet lab, to design and engineer therapeutic antibodies with superior functionality. BigHat...

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense (“DoD”) is providing $876,000 to advance a strategy to ident...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced three poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, being held April 25 – 30, 2025 in Chicago, IL. AACR poster presentation details are below: MOMA-313 is a potent and selective inhibitor of the Polθ DNA helicase domain for the treatment of HR-deficient tumors Ses...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. “We are honored to welcome Michael t...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investo...